| Company Name: |
Zhejiang Huida Biotech Co., LTD
|
| Tel: |
0571-89903022 18679456698 |
| Email: |
zilong@hizyme.com |
| Products Intro: |
Product Name:Erbstatin
CAS:100827-28-9
Purity:99% HPLC Package:10mg；100mg；1g；10g；100g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Erbstatin
CAS:100827-28-9
Package:1mg/RMB 8660
|
(E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide manufacturers
- Erbstatin
-
- $1230.00
-
2026-05-11
- CAS:100827-28-9
- Purity:
- Supply Ability: 10g
|
| | (E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide Basic information |
| | (E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide Chemical Properties |
| storage temp. | -20°C | | solubility | Acetone: Soluble,DMSO: Soluble,Methanol: Soluble | | form | A solid |
| | (E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide Usage And Synthesis |
| Uses | Erbstatin, a EGFR kinase inhibitor, possesses antineoplastic effect[1][2]. | | References | [1] Shigeki Kobayashi, et al. Diastereomer-specific effects of double-stranded peptides conjugated with -L-Tyr-L-Phe- or -L-Tyr-D-Phe- residues on tyrosine phosphorylation and inhibition of src(ts)NRK, A431, MCF-7, and DU145 cell growth. Chem Pharm Bull (Tokyo). 2007 Nov;55(11):1585-92. DOI:10.1248/cpb.55.1585
[2] M Toi, et al. Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice. Eur J Cancer. 1990;26(6):722-4. DOI:10.1016/0277-5379(90)90126-e
[3] S Simizu, et al. Involvement of hydrogen peroxide production in erbstatin-induced apoptosis in human small cell lung carcinoma cells. Cancer Res. 1996 Nov 1;56(21):4978-82. PMID:8895753 |
| | (E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide Preparation Products And Raw materials |
|